kpl-387
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2025 (NCT07010159)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-1 receptorINHIBITOR
IL1R1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07288216 | Phase 2 | Jan 31, 2026 | Kiniksa Pharmaceuticals, Ltd. |
| NCT07010159 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2025 | Kiniksa Pharmaceuticals, Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | For profit | 2 | 2 | 2 | 2025 |
1 organizations
Page 1 / 1